Background and Objective: Tumer necrosis factor alfa )TNF-α (inhibitors are the initial choices for treating moderate to severe cases of plaque psoriasis. Even though they are safe and effective, many patients exhibit poor responses in clinical practice. Genetic variables that could impact the efficacy of biological therapies may impact this response variability. This review assesses research on psoriasis that focuses on the impact of genetic variations in the TNF Alfa and some additional genes in the TNF signaling pathway on drug response.
Methods: This review was conducted between May and June 2024, utilizing the Google Scholar and PubMed databases. Search terms included: “psoriasis”, “psoriatic”, together with “treatment”, “biological therapy”, “Anti-TNF alfa”, “polymorphisms”, “TNF alfa gene”,” TNFRSF1B, TNFRSF1A, TNFAIP3, FCGR2A, FCGR3A. IL1B” and “response”.
Results: This search identified 20 studies that examined the relationship between genetic polymorphism and response to anti-TNF-α therapy in patients with moderate-to-severe psoriasis. These polymorphisms include:           TNF-α: -238 (rs361525), -308 (rs1800629), -857 (rs1799724), -1031 (rs1799964), TNF-α receptor (TNFRSFB1): rs1061622, TNFAIP3: rs610604, FCGR2A: H131R (rs1801274), FCGR3A: V158F (rs396991) and IL1B (rs1143623 and rs1143627).
Conclusion: These genetic variations may serve as valuable predictive biomarkers for individualizing anti-TNF treatment strategies in this patient population.